OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
What Is the Best Prostate Cancer Treatment? Why Precision Beats Surgery
What if the best prostate cancer treatment doesn’t cut, burn, or destroy your vitality — yet still teaches your immune system to find and fight cancer throughout the body?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology and interventional radiology are redefining prostate cancer care. Instead of relying on radical surgery or radiation, Envita uses deep DNA/RNA sequencing, immune profiling, and 3D cone-beam imaging to guide minimally invasive, immune-centered procedures.
Dr. Prato discusses the risks of standard prostate surgery — including incontinence, erectile dysfunction, and long-term recurrence — and how precision targeting eliminates guesswork by treating the tumor directly and stimulating the immune system for long-term remission.
🎯 What You’ll Learn in This Episode:
• Why up to 50% of men experience PSA recurrence after prostate surgery
• How interventional oncology delivers treatment directly to the tumor site
• Why immune-based, precision care improves long-term outcomes
• The difference between radical surgery and image-guided microcatheter treatment
• How DNA, RNA, and spatial biology testing reveal cancer’s weak points
• Why deep mapping prevents recurrence and protects quality of life
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“The future of prostate cancer care is precise, personalized, and immune-centered.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493